Cardiac Left Atrial Evaluation and Response in HFrEF With Sacubitril/Valsartan

NCT ID: NCT07088471

Last Updated: 2025-08-06

Basic Information

• Recruitment Status: ACTIVE_NOT_RECRUITING
• Total Enrollment: 334 participants
• Study Classification: OBSERVATIONAL
• Study Start Date: 2024-11-01
• Study Completion Date: 2025-08-01

Brief Summary

Heart failure is an increasingly common condition that can have a significant impact on quality of life and reduce life expectancy. In recent decades, a number of drugs have been developed specifically for this condition. One such drug, called Sacubitril/valsartan (SV) has been shown to reduce hospitalizations and prolong life expectancy of patients with heart failure. It works by reversing some of the structural and functional changes to the heart that occur in heart failure. However, not all patients respond to the drug. Further research is needed to better understand the reasons for this and predict who will benefit most from the drug.

Left atrial strain is a relatively new measurement that can be obtained using ultrasound imaging of the heart, and it provides objective information about how one of the heart's four chambers is functioning. The investigators aim to assess the effect of SV therapy on left atrial strain in patients with heart failure. The investigator's objective is to understand whether abnormal left atrial strain or changes in left atrial strain help predict response to SV therapy.

Detailed Description

Sacubitril/valsartan (SV) improves cardiovascular outcomes in patients with heart failure and reduced ejection fraction (HFrEF) [1]. However, not all patients respond to therapy. SV therapy has been shown to promote reverse cardiac remodelling, which may contribute to its efficacy in responders [2].

Left atrial (LA) remodeling has been shown to be related to a variety of cardiovascular diseases. Until recently, the LA was only considered to act as a conduit for the left ventricle, and we now know that the LA plays a dynamic role throughout the cardiac cycle. Currently, LA volume is recommended by the European Society of Cardiology for the evaluation of LA size and remodeling [2]. Over the last decade, advancements in echocardiographic software have led to the development of novel parameters to measure LA function and remodeling. LA function is now divided into three phases: reservoir, conduit, and contractile phase.

Recently, speckle tracking on 2-dimensional echocardiography has been used to evaluate LA Strain. LA strain has been evaluated in clinical studies and has been shown to be a useful tool in the diagnosis of LA remodeling when compared to conventional methods. A recently published study from Korea has defined the reference ranges for LA strain in a healthy population [3]. Along with the reference range, the same study also looked at different determinants of LA strain [3]. LA strain by speckle tracking echocardiography is an affordable, non-invasive, pragmatic, diagnostic tool that can be performed as part of the standard 2D echocardiogram.

There have been limited studies assessing the relationship between SV therapy and LA strain. The investigators aim to evaluate the hypothesis that baseline LA strain and any changes associated with SV therapy may be a prognosticator of response to therapy in HFrEF patients.

Conditions

Heart Failure and Reduced Ejection Fraction

Study Design

• Observational Model Type: CASE_ONLY
• Study Time Perspective: RETROSPECTIVE

Interventions

Sacubtril/Valsartan

Angiotensin-receptor blocker and neprilysin inhibitor therapy

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

1. Adults diagnosed with heart Failure with reduced ejection fraction (HFrEF), i.e. LVEF ≤40% by Simpson's method on transthoracic echocardiography

2. Stable guideline-directed medical therapy prior to sacubitril/valsartan (SV) initiation

3. New York Heart Association classes II-III symptom status

4. Guideline-directed up-titration of SV therapy to the maximum tolerated dose

5. Transthoracic echocardiogram and NT-proBNP prior to SV initiation and at 3 months post commencement of therapy

Exclusion Criteria

1. Patients not in sinus rhythm at time of echocardiograms (precludes left atrial strain analysis)

2. Sub-optimal echocardiographic images to allow measurement of left atrial strain

3. Prior mitral valve intervention (left atrial strain assessment unreliable in this cohort)

4. Severe mitral regurgitation (left atrial strain assessment unreliable in this cohort)

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Connolly Hospital Blanchardstown

OTHER

Sponsor Role: lead

Responsible Party

Michael J Daly, MA MD PhD

Dr

Responsibility Role: PRINCIPAL_INVESTIGATOR

Locations

Connoly Hospital Blanchardstown

Dublin, , Ireland

Countries

Ireland

Other Identifiers

CHB 005/25

Identifier Type: -

Identifier Source: org_study_id